Get the Stockscreener App
329.13
0.01%
-0.005
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $329.13, with a volume of 729.43K.
It is down -0.01% in the last 24 hours and down -0.22% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$329.13
Open:
$326.17
24h Volume:
729.43K
Relative Volume:
0.29
Market Cap:
$177.66B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
22.89
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
-2.04%
1M Performance:
-0.22%
6M Performance:
-2.74%
1Y Performance:
+14.08%
1-Day Range:
$322.30
$329.28
1-Week Range:
$322.30
$341.39
52-Week Range:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
329.18 | 177.63B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,070.78 | 965.04B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
224.05 | 538.04B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.62 | 376.20B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
116.62 | 284.45B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
177.53 | 278.70B | 60.48B | 10.40B | 8.05B | 3.3297 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc. stock (US0311621009): EU approves Imdylltra as shares ease from recent highs - AD HOC NEWS
The Next Era in Obesity Care - Amgen
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication - TradingView
EC approval for Amgen’s Imdylltra - The Pharma Letter
BNP Paribas Acquires 38,554 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. stock (US0311621009): EU approval for IMDYLLTRA adds fresh catalyst - AD HOC NEWS
Amgen Inc. stock underperforms Monday when compared to competitors - MarketWatch
EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER - PR Newswire
Amgen Inc. stock (US0311621009): Shares open lower in New York - AD HOC NEWS
Amgen shares dip amid rising selling pressure - Traders Union
When Culture Meets Care: Bringing Cardiovascular Screening to the Heart of New Orleans - Amgen
(AMGN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Peapack Gladstone Financial Corp Sells 8,887 Shares of Amgen Inc. $AMGN - MarketBeat
MUFG Securities EMEA plc Boosts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN) Stock Analysis: Navigating a 4.59% Potential Upside Amid Strong Revenue Growth - DirectorsTalk Interviews
Easterly Investment Partners LLC Reduces Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc stock (US0311621009): Nasdaq shares hold near 337 USD as investors weigh Q1 2026 results a - AD HOC NEWS
Amgen Inc. stock (US0311621009): shares hover in mid-330 USD range as market digests Q1 2026 beat an - AD HOC NEWS
How The Amgen (AMGN) Story Is Evolving As Rare Disease Upside Meets Valuation Caution - Yahoo Finance
Amgen Inc. stock (US0311621009): shares steady around 340 USD as investors weigh Q1 numbers and R&D - AD HOC NEWS
Nomura Asset Management Co. Ltd. Has $97.92 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Commonwealth of Pennsylvania Public School Empls Retrmt SYS - MarketBeat
Amgen Stock: Is AMGN Outperforming the Healthcare Sector? - Barchart.com
Amgen Inc. stock (US0311621009): shares little changed as investors digest recent earnings and drug - AD HOC NEWS
Norges Bank Buys New Position in Amgen Inc. $AMGN - MarketBeat
Savant Capital LLC Trims Stock Position in Amgen Inc. $AMGN - MarketBeat
Eurizon Capital SGR S.p.A. Invests $86.74 Million in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. stock (US0311621009): Upcoming Jefferies appearance keeps focus on US biotech heavyweight - AD HOC NEWS
Amgen To Present At Jefferies Global Healthcare Conference - Weekly Voice
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE - marketscreener.com
Amgen Inc. stock (US0311621009): shares steady as Nasdaq biotech name trades near recent range - AD HOC NEWS
Amgen Inc. $AMGN Shares Acquired by National Pension Service - MarketBeat
Ilmarinen Mutual Pension Insurance Co Has $28.54 Million Position in Amgen Inc. $AMGN - MarketBeat
Intech Investment Management LLC Grows Holdings in Amgen Inc. $AMGN - MarketBeat
17,124 Shares in Amgen Inc. $AMGN Acquired by Fideuram Asset Management Ireland dac - MarketBeat
RTX, Wells Fargo (WFC) And Amgen (AMGN) Face Mixed Outlooks As Analysts Weigh Growth Against Key Risks - foreignpolicyjournal.com
Amgen Inc. stock (US0311621009): Shares steadier as S&P 500 biotech name trades around recent range - AD HOC NEWS
Has Amgen Stock Quietly Become a Value Opportunity? - Trefis
Amgen Inc. stock (US0311621009): Venture arm backs cold-chain specialist Ember LifeSciences - AD HOC NEWS
Possible Bearish Signals With Amgen Insiders Disposing Stock - Yahoo Finance
Amgen Inc. $AMGN Shares Purchased by Smith Chas P & Associates PA Cpas - MarketBeat
Amgen Inc. $AMGN Stake Boosted by Integrity Alliance LLC. - MarketBeat
Foundations Investment Advisors LLC Buys 3,292 Shares of Amgen Inc. $AMGN - MarketBeat
Geode Capital Management LLC Has $4.67 Billion Stock Position in Amgen Inc. $AMGN - MarketBeat
AMGN Technical Analysis | Trend, Signals & Chart Patterns | AMGEN INC (NASDAQ:AMGN) - ChartMill
Amgen stock (US0311621009): Focus on earnings, pipeline, and US market exposure - AD HOC NEWS
Amgen Inc. stock (US0311621009): Weight-loss trial update keeps biotech giant in focus - AD HOC NEWS
Amgen Inc. stock (US0311621009): Investors weigh steady Q1 growth, Horizon deal integration and pipe - AD HOC NEWS
Amgen Presents 2nd Community Day as L.A. Builds Momentum for Kick Off of FIFA World Cup 2026 - Amgen
President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too? - The Motley Fool
Amgen Ventures Makes Strategic Investments in Cold Chain Firm Ember LifeSciences - Moomoo
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):